antibodies(mAbs) are just like antibodies except they are artificially
produced from the clones of a single cell.
antibodies are made by multiple, identical copies (i.e. clones) of a
cell called a hybridoma.
antibodies are produced by fusing single antibody-forming cells to tumor
cells grown in culture. The resulting cell is called a
antibodies are created with cell fusion technology and cell culture
- Once a monoclonal
antibody is made, it can be used as a specific probe to track down and
purify the specific protein that induced its formation.
antibodies can be used to classify strains of a single pathogen, e.g.
Neisseria gonorrhoeae can be typed using monoclonal
antibodies are widely used as diagnostic and research reagents. Their
introduction into human therapy has been much slower.
antibodies (MABs or MOABs) work on cancer cells in the same way natural
antibodies work, by identifying and binding to the target
- The market for
therapeutic monoclonal antibodies (mAbs) is one of the most dynamic
sectors within the pharmaceutical industry.
- The current global
clinical antibody pipeline, which comprises 132 products in development
and is dominated by humanized (42%) and fully human (28%)mAbs, is poised
to deliver as many as 16 new products between 2004 and 2008.
- As a result of
growth in existing markets for mAb therapeutics,and the opening of new
ones, the global market is projected to increase to US $16.7 billion in
- The mAbs market is
expected to almost triple in value over the next six years from $10.3
billion in 2004 to $30.3 billion. Oncology products will continue to
dominate the market. However, sales of arthritis, immune and
inflammatory disorders (AIID) products are forecast to grow strongly and
account for 40.1% of the market by 2010.
- Chimeric mAbs were
the undisputed leaders,with 43% growth and US $3.8 billion in sales,
followed by humanized
mAbs with more than US $1.4 billion in sales
and growth of 29%.
- The development
focus of the industry is moving away from murine and chimeric
antibodies, to humanized and, in particular, fully human technologies. A
wave of fully human products are expected to launch from 2007 onwards,
accounting for 12 of the 20 launches between 2007 and 2010.
- Roche and
Genentech dominate the mAbs market, with a combined market share of
44.9% in 2004, although this is forecast to slip to 35.7% in 2010.
- Next generation
antibodies are forecast to drive the market towards the $30 billion mark
by 2011 due to a high level of innovation in early-stage discovery and
several potential nichebusters set to launch in the next 5
- Applications of
Monoclonal Antibodies include: Identification of Cell Surface Markers ,
Detection Assays , Purification Techniques , Gene Identification ,
Disease Therapy , Use in Applied Chemistry
want the information can E-Mail us to